Fundz

Amagma, Inc. reported raising $2.28 Million in an initial SEC Form D filing, from an offering of $2.28 Million

PRIVATEJun 01, 2022

Amount Raised

$2.28 Million

$2.28 Million sold, per SEC Form D (first sale Jun 1, 2022)

Round Type

Seed

WalthamBiotechnologyHealthcare

Quick answer

Amagma, Inc. raised $2.28 Million in a Seed round, dated June 1, 2022. Amagma, Inc. is based in Waltham, Massachusetts, United States.

How much did Amagma, Inc. raise?
Amagma, Inc. raised $2.28 Million in a Seed round on June 1, 2022.
What does Amagma, Inc. do?
Amagma Therapeutics is a startup biotechnology company founded by proven serial entrepreneurs including Prof.
Where is Amagma, Inc. based and how big is it?
Amagma, Inc. is based in Waltham, Massachusetts, United States.

Source: Fundz verified event record.

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Amagma, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Renibus Therapeutics raised $15M on July 15, 2022.
  • Greenbrook TMS raised $16M on July 14, 2022.
  • Ensysce Biosciences raised $4.2M (Seed) on July 8, 2022.
  • Kernal Biologics raised $25M (Series A) on July 7, 2022.
  • X4 Pharmaceuticals raised $56M on July 6, 2022.
  • Ascendia Pharmaceuticals raised $2.5M on July 1, 2022.

Who to call at Amagma, Inc., and when

A new round usually means Amagma, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Amagma, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Amagma, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Amagma, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Amagma, Inc.

Location

100 BEAVER STREET

Waltham, Massachusetts, United States

About

Amagma Therapeutics is a startup biotechnology company founded by proven serial entrepreneurs including Prof. Tillman Gerngross and Prof. Leonard Zon. Amagma scientists are working on the discovery and development of antibody therapeutics against inflammatory diseases (with a focus on GI disorders) which have proven intractable by other approaches. Amagma is based in Waltham, Massachusetts, and funded by private investors including Polaris Partners.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Amagma, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Amagma, Inc.'s next move

See what Strategic adds

Amagma, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.